Clinical and pathological characteristics of LRRK2 G2019S patients with PD

Journal of Molecular Neuroscience

Volumn 47, Issue 1, 2012, Pages 139-143

  Poulopoulos, Markos ^a   Cortes, Etty ^a   Vonsattel, Jean Paul G ^a   Fahn, Stanley ^a   Waters, Cheryl ^a   Cote, Lucien J ^a   Moskowitz, Carol ^a   Honig, Lawrence S ^a   Clark, Lorraine N ^a   Marder, Karen S ^a,b,c   Alcalay, Roy N ^a,d  

^a Columbia University ^*  (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Dementia; Lewy bodies; LRRK2 gene mutation; Parkinson's disease

Indexed keywords

AMYLOID; CARBIDOPA PLUS LEVODOPA; GLYCINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; SERINE; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOIDOSIS; ARTICLE; AUTOPSY; BRAIN; BRAIN CORTEX; BRAIN DEPTH STIMULATION; BRAIN STEM; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE DEFECT; COLOMBIA; CREUTZFELDT JAKOB DISEASE; CROSS-SECTIONAL STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DYSKINESIA; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOTE; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NEUROPATHOLOGY; PALLIDOTOMY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; RISK FACTOR; TAUOPATHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; GENOTYPE; HUMANS; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; RETROSPECTIVE STUDIES; RISK FACTORS;

PARKINSONIA;

EID: 84859718086     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-011-9696-y     Document Type: Article

References (23)

1. Belarbi S, Hecham N et al (2010) LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. Parkinsonism Relat Disord 16 (10):676-679
2. Braak H, Del Tredici K et al (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2):197-211 (Pubitemid 36007810)
3. Dachsel JC, Ross OA et al (2007) Lrrk2 G2019S substitution in fronto-temporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol 113(5):601-606 (Pubitemid 46672607)
4. Daniel SE, Lees AJ (1993) Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165-172 (Pubitemid 23216938)
5. Gaig C, Marti MJ et al (2007) G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatr 78(6):626-628 (Pubitemid 46853900)
6. Gaig C, Ezquerra M et al (2008) Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270(1-2):94-98 (Pubitemid 351766729)
7. Giasson BI, Covy JP et al (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59(2):315-322 (Pubitemid 43202485)
8. Gilks WP, Abou-Sleiman PM et al (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (9457):415-416 (Pubitemid 40179229)
9. Gomez A, Ferrer I (2010) Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol 120(2):155-167
10. Healy DG, Falchi M et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7(7):583-590
11. Hely MA, Reid WG et al (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837-844
12. Hughes AJ, Daniel SE et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 55(3):181-184
13. Lesage S, Durr A et al (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354(4):422-423 (Pubitemid 43145082)
14. Lippa CF, Smith TW et al (1994) Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 35 (1):81-88 (Pubitemid 24027610)
15. Marder KS, Tang MX et al (2010) Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol 67(6):731-738
16. Ozelius LJ, Senthil G et al (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354 (4):424-425 (Pubitemid 43145083)
17. Ozelius LJ, Foroud T et al (2007) G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord 22(4):546-549 (Pubitemid 46608154)
18. Rajput A, Dickson DWet al (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67(8):1506-1508
19. Ross OA, Toft M et al (2006) Lrrk2 and Lewy body disease. Ann Neurol 59(2):388-393 (Pubitemid 43202496)
20. Silveira-Moriyama L, Guedes LC et al (2008) Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology 71(13):1021-1026
21. Umeno J, Asano K et al (2011) Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 17(12):2407-2415
22. Wider C, Dickson DW et al (2010) Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis 7(1-3):175-179
23. Zimprich A, Biskup S et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601-607 (Pubitemid 39531225)